In a double-blind, randomized study, we compared the healing of gastric ulcer during a twice-daily regimen of 2 g sucralfate or sucralfate 1 g q.i.d. Patients receiving the former therapy received the tablets one-half hour before breakfast and at bedtime. Patients receiving sucralfate 1 g q.i.d. received their therapy 30 minutes before breakfast, lunch, and supper, and at bedtime. The study included 52 patients with endoscopically proven gastric ulcer; 41 patients completed the study. Healing was endoscopically assessed at 8 weeks and 12 weeks. After 8 and 12 weeks the healing rate for sucralfate 2 g b.i.d. was 67% and 92%, respectively; the healing rate of sucralfate 1 g q.i.d. was 59% and 71%, respectively. No statistically significant difference was found between the two regimens. The results suggest that 2 g sucralfate twice daily is as effective in the healing of gastric ulcer as 1 g sucralfate q.i.d.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9343(91)90454-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endoscopic Management of Recalcitrant Marginal Ulcers by Covering the Ulcer Bed.
Obes Surg
August 2018
Department of Medicine and Division of Gastroenterology and Hepatology, The Johns Hopkins Medical Institutions, 4940 Eastern Avenue, A Building, 3rd floor 600 N Wolfe St, Baltimore, MD, 21287, USA.
Background: Management options for marginal ulcers (MU) vary from medical therapy to revision surgery. Medical therapy is often ineffective and revision surgery is associated with a high morbidity and possible recurrence.
Aims: To evaluate technical feasibility, efficacy, and safety of endoscopic management of MU by covering the ulcer bed using oversewing and/or deploying a fully covered self-expandable metallic stent (FCSEMS).
Doxycycline-induced ulceration mimicking esophageal cancer.
Cases J
September 2008
Department of Gastroenterology, Pasabahce State Hospital, Istanbul, Turkey.
Introduction: Doxycycline-induced esophageal ulcer patients are mostly young persons with no history of esophageal dysfunction. Heartburn, midsternal pain and dysphagia are the most common symptoms. It has generally a benign course.
View Article and Find Full Text PDFRole of anti-Helicobacter pylori treatment in H. pylori-positive and cytoprotective drugs in H. pylori-negative, non-ulcer dyspepsia: results of a randomized, double-blind, controlled trial in Asian Indians.
J Gastroenterol Hepatol
June 1999
Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi.
Background: The efficacy of anti-Helicobacter pylori treatment and cytoprotective drugs in H. pylori-positive and -negative non-ulcer dyspepsia (NUD), respectively, is debatable.
Methods: In a randomized study, the efficacy of anti-H.
Sucralfate as an alternative to bismuth in quadruple therapy for Helicobacter pylori eradication.
Helicobacter
September 1997
Gastroenterology Unit, Monash Medical Centre, Melbourne, Australia.
Background: There are persuasive arguments for treating all patients with Helicobacter pylori-associated peptic ulcer disease. However, the choice of therapeutic regimen remains problematical. Bismuth triple therapy produces greater than 80% cure of H.
View Article and Find Full Text PDFTriple therapy with sucralfate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers.
Am J Gastroenterol
September 1995
Department of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong.
Unlabelled: Triple therapy with bismuth, metronidazole, and tetracycline or amoxicillin is effective for the treatment of Helicobacter pylori, but side effects are common. Sucralfate inhibits H. pylori hemagglutinin, protease, and lipase and thus might affect colonization of the bacterium in the stomach.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!